 
               NCT 02556736 
 
Study ID: RST-001-CP-0001 
 
 
Title: Phase I/IIa, Open -Label, Dose- Escalation Study of Safety and Tolerability of 
Intravitreal RST -001 in Patients with Advanced Retinitis Pi[INVESTIGATOR_1802] (RP)  
 
                                       Protocol Date: 19- Oct-2017  
 
 
Approval Date :  
 19-Oct-2017Allergan  Protocol RST-001-CP-0001 Amendment 2
 
1 ALLERGAN  
 
 
The following contains  proprietary information  
which is the property of Allergan, Inc. 
 
Phase I/IIa, Open-Label, Dose-Escalation Study of  
Safety and Tolerability of Intravitreal RST-001 in  
Patients with Advanced Re tinitis Pi[INVESTIGATOR_1802] (RP) 
 
Protocol Number:   RST-001-CP-0001, Amendment 2 
Phase: Phase 1/2a 
Name [CONTACT_791]: RST-001 (AGN-151597) 
Sponsor: 
 Allergan, Inc. 
[ADDRESS_803017] 
Irvine, [LOCATION_004] [LOCATION_003] [ZIP_CODE] +[PHONE_10421] +[PHONE_10422]  
Emergency Telephone Number(s): No rth America:
Serious Adverse Event Reporting Fax Number(s): 
Allergan Medical Safety Physician 
Contact [CONTACT_7171]: 

 
 
Approval Date :  
 19-Oct-2017Allergan  Protocol RST-001-CP-0001 Amendment 2
 
2 Allergan Signatory: 
Therapeutic Area Head 
Glaucoma and Retina 
Allergan – Global Drug Development  
Refer to the final page of this protocol for electronic signature 
[CONTACT_51472]. 
 
 
 
The following information can be found on [LOCATION_002] FDA Form 1572 and/or study contacts 
page and/or the Trial Master Fi le: Name [CONTACT_3669] [CONTACT_606206]; name, address,  and statement of qualifications of each 
investigator; name [CONTACT_606227]; 
name [CONTACT_606228] (IRB); US 21 CFR 312.23 
section 6(iii)b. 
 

 
 
Approval Date :  
 19-Oct-2017Allergan  Protocol RST-001-CP-0001 Amendment 2
 
3 INVESTIGATOR SIGNATURE [CONTACT_606229]: 
I agree to: 
• Implement and conduct this study diligently  and in strict compliance with the 
protocol, good clinical practices and all applicable laws and regulations. 
• Maintain all information supplied by [CONTACT_249595], when this 
information is submitted to an Institutiona l Review Board (IRB), Independent Ethics 
Committee (IEC) or another group, it will be submitted with a designation that the material is confidential. 
• Ensure that all persons assisting with the study are ade quately informed about the 
protocol, the investigational product(s), and their study-related duties and functions. 
 
I have read this protocol in its en tirety and I agree to all aspects. 
 
 
 
Investigator Printed Name   [CONTACT_606230] :  
 19-Oct-2017Allergan 
 
 [ADDRESS_803018]
reatments  
Identity of Dosage anMethod of Dose RatioPatient
 and e of Cont e
ontents  ........
......................................
ynopsis ........
n .................
d and Ratio n
gmentosa ( R
atures  ..........
thology .......
is ................
...................
ociated Vir u
nt AA V Vec t
nical Experi e
...................
l Studies wi t
ogy Studies  .
and Biodis t
n for Huma n
tudy Ration a
nicity of RS T
Administrati
of the Stud y
bjective:  ......
Objectives:  
uct and GC P
Benefits .......
isks ............
from Risks  .
for Injury  ...
enefits  ........
fit Analysis  ..
rview  ..........
gn ...............
ulation  .........
Criteri a .......
ontinuation o
...................
Investigatio n
d Administr a
Assigning P a
nale ............
Investigato rents 
................... .
................... .
................... .
................... .
................... .
nale ............. .
RP) .............. .
................... .
................... .
................... .
................... .
us ................ .
tors ............ .
ence with A A
................... .
th RST-[ADDRESS_803019] u
n Dose ........ .
ale: Optoge n
T-[ADDRESS_803020]-001-CP
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
ced Retiniti s
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .-0001 Amend m
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
s Pi[INVESTIGATOR_43697] a
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .ment 2
.......4 
...... 8 
...... 9 
.....10 
.....13 
.... 13 
.... 13 
.... 13 
.... 13 
.... 13 
.... 14 
.... 14 
.... 14 
.... 14 
.... 14 
.... 15 
.... 15 
.... 16 
.... 18 
a .. 18 
.... 19 
.... 19 
.... 19 
.... 19 
.... 19 
.... 20 
.... 20 
.... 20 
.... 20 
.... 21 
.... 21 
.... 21 
.... 21 
.... 21 
.... 24 
.... 24 
.... 26 
.....27 
.... 27 
.... 27 
.... 27 
.... 27 
.... 28 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
4.[ADDRESS_803021] InjectiDay 7 ........Month 1  ....
Month 3  ....
Month 6: PMonth 9  ....
Month 12  ..
Month 18  ..
Month 24 (Long-term DescriptioInform
ed 
Medical Hi
Concomita
Adverse EPhysical EPregnancy Blood Sam
T
reatment and Labelin g
nd Storage  ..
tment Prepa r
countability
t of Compli a
of RST-001 O
Concomitant 
ssments an d
f Procedure s
Consent and P
Visit ............
isit ..............
Visit (Day 0 )
on Visit (D a
...................
......................................
rimary End p
.........................................................
or Early Ter
Follow-up V
n of Study P r
Consent ........
story (Revi e
nt Medicati o
vent Review  
xamination ..
Test ............
ple ..............
Administratig ................. .
................... .
ration and A
................... .
ance ............ .
Overdose  ....
Therapy  ......
d Intravitreal 
s by [CONTACT_4838]  .....
Patient Priv a
................... .
................... .
) ................. .
ay 1) ............ .
................... .
................... .
................... .
point ........... .
................... .
................... .
................... .
mination) V
Visits ........... .
rocedures  ....
................... .
ew) .............. .
ons and Pro c
................... .
................... .
................... .
................... .
on .............. .
[ADDRESS_803022]-001-CP
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .-0001 Amend m
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .ment 2
.... 28 
.... 28 
.... 28 
.... 29 
.... 29 
.... 29 
.... 29 
.....29 
.... 32 
.... 32 
.... 32 
.... 33 
.... 34 
.... 34 
.... 35 
.... 35 
.... 35 
.... 36 
.... 36 
.... 37 
.... 37 
.... 38 
.... 38 
.... 39 
.... 39 
.... 39 
.... 40 
.... 40 
.... 40 
.... 40 
.... 40 
.... 43 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
5.3.[ADDRESS_803023] Injecti
ManagemeSafety Ass
Overview 
Ocular SafSystemic SClinical MIntraocular ComplicatiOccupatioPregnancy Data Safet
Co
mpositi
Role ..........
ResponsibiEnrollment Adverse E
Definitions
Adverse ESerious AdSeverity  ....
RelationshiProcedures Procedures Efficacy A
Clinica
l M
Monitoring
Study and Data Analy
Primary (S
Secondary Measures 
o
AnatomicaStatistical Power and Baseline CSafety AnaEfficacy AOther AnalInterim AnInvestigato
Data HandData Manaon Medicati
nt of Post I nj
essments  .....
of Safety As s
ety Measure m
afety Meas u
anagement o
Inflammati o
ons of the I n
nal Safety  ....
and Exposu r
y Monitorin g
on ................
...................
lities ...........
Stoppi[INVESTIGATOR_007] R u
vents ...........
...................
vent .............
verse Event  
...................
p to Study D
for Reporti n
for Reporti n
ssessments  ..
onitoring St r
 ..................
Site Closure  
sis and Stat i
afety) Endp o
Endpoints  ..
f Change in 
l Endpoints R
Analysis Pla n
Sample Siz e
haracteristic s
lysis............
nalysis  ........
ysis .............
alysis ..........
r Responsib i
ling and Re c
gement Res pons ............. .
njection Intr a
................... .
sessments  ....
ments ......... .
urements ..... .
of Safety Pa r
on and Imm u
ntravitreal I nj
................... .
re to RST-[ADDRESS_803024] Keepin g
ponsibilities .
6 ...................
aocular Pres
...................
...................
...................
...................
rameters  ......
unogenicity 
njection  .......
...................
01 In Utero  .
e (DSMC)  ...
...................
...................
...................
...................
...................
...................
...................
...................
...................
dy Procedur
Events  ........
Adverse E
...................
...................
...................
...................
derations  ....
...................
...................
tion ............
Retinal Inte
...................
ions ............
...................
...................
...................
...................
...................
...................
g .................
...................Protoco
...................
sure ............
...................
...................
...................
...................
...................
Related to 
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................
e ..................
...................
vent .............
...................
...................
...................
...................
...................
...................
...................
...................
grity and Su
...................
...................
...................
...................
...................
...................
...................
...................
...................
...................l RST-001-CP
................... .
................... .
................... .
................... .
................... .
................... .
................... .
RST-001  ......
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
rvival  ......... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .-0001 Amend m
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .ment 2
.... 43 
.... 43 
.....43 
.... 43 
.... 43 
.... 45 
.... 45 
.... 46 
.... 46 
.... 46 
.... 47 
.....47 
.... 47 
.... 47 
.... 47 
.... 48 
.....48 
.... 48 
.... 48 
.... 49 
.... 50 
.... 50 
.... 50 
.... 50 
.....51 
.....51 
.... 52 
.... 52 
.....52 
.... 52 
.... 52 
.... 52 
.... 53 
.... 53 
.... 53 
.... 54 
.... 54 
.... 54 
.... 54 
.... 54 
.....54 
.....55 
.... 55 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
13.1.1 
13.1.2 
 14
 15
15.1 
 16
16.1 
 17
 18
 19
 20
20.1 
20.2 
20.3 
20.4 
 
 Data Quali
Source DoStudy Ter
Regulatory Ethical Co
Manageme
Protocol A
Publicatio
n
Sponsor's 
References  
AppendiceAppendix 
Appendix Protocol AProtocol Aty Assuranc e
cuments  ......
mination  .......
and Ethical 
nduct of the 
nt of Protoc o
mendments  .
 Policy  .......
Final Report  
...................
s ..................
1: Abbreviat i
2: Clinical L a
mendment S
mendment Se .................. .
................... .
................... .
Considerati
Study ......... .
ol Amendm e
................... .
................... .
................... .
................... .
................... .
ions ............ .
aboratory T e
ummary A m
ummary A m
[ADDRESS_803025]-001-CP
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .-0001 Amend m
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .
................... .ment 2
.... 55 
.... 56 
.....56 
.....56 
.... 57 
.....59 
.... 59 
.....59 
.....59 
.....60 
.....61 
.... 61 
.... 62 
.... 64 
.... 83 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-[ADDRESS_803026] of Tables 
Table 1 Dose Escalation  .......................................................................................................... 23  
Table 2 Study Visit Schedule: Core Study Visits  .................................................................... 31  
Table 3 Study Visit Schedule: Long-term Follow-up Visits  .................................................... 32  
Table 4 Biomicroscopic Grading of Ante rior Chamber Cells and Flare  ................................. 44  
 
 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-[ADDRESS_803027] of Figures 
Figure 1 Overview of the Treatment Schedule  ......................................................................... 23  
 
 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
12 Clinical Study 
progress Patients will be enrolled sequentially. The decision to dose escalate will be determined with the DSMC upon review of adverse events (AE), clinical evaluations (ocular and systemic) and laboratory results. 
Monitoring of safety 
and tolerability Safety monitoring will include a combination of AE reporting, clinical evaluations (ocular and systemic), and laboratory results. 
Ocular and systemic safety monitoring will include monitoring for signs of an immune response.  
Enrollment Stoppi[INVESTIGATOR_606195] 3 (Common Terminology Criteria [CTC] for AEs v4.03) or greater AE considered related to the study treatment. 
Primary endpoints: 
Assessment of safety The primary endpoint is safety at [ADDRESS_803028]-001 in improving visual function as measured by a series of psychophysical , electrophysiological and anatomical 
measures. 
Analysis plan The sample size for this study was chos en empi[INVESTIGATOR_3675]; no formal sample size 
computations to meet power requireme nts were made. The sample size of 
approximately [ADDRESS_803029] deviation, minimum, median and maximum. 
 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
 [ADDRESS_803030] po
ation finding
te bone-spi c
on.  
Cell
marily a dis
es (Daiger e
igment epit
clude cell r
anglion cell
ons with the 
Path
e large num
se molecula
the photorecoduction 
kground a n
nitis pi [INVESTIGATOR_606196]
(RP) is a h e
d that the pr e
(Sohocki et a
prevalence r
ed ocular di s
erogeneous w
ntified. In th e
ical featu r
sts as night-
al field const r
al acuity (V A
or V A and m
s include ab n
ules, outer r
ular path o
ease of the r
t al., 2007 ). 
helium. Loss 
eorganizatio n
s, which co m
brain. 
ogenesis 
ber of causa t
r pathology 
eptor cells end Ratio n
entosa (R P
ereditary, sl o
evalence of R
al., 2001) w i
rate is thoug h
sease thoug h
with more t h
e U.S., RP i s
res 
blindness a n
ricts relativ e
A) is preserv e
minimal pres e
normal pig m
retinal atrop h
ology 
od photorec e
Cone photo r
of the phot o
n, disorgani z
mprise the in n
tive genes a n
of RP remai
eventually re
13 nale 
P) 
owly-progre
RP in the U
ith 10-20% 
ht to occur w
h it is a man
han forty ca
s most com
nd peripher
ely symmetr
ed until adv
erved visual 
mentary cha n
hy, optic ner
eptors whic
receptors su
oreceptors r
zation and c e
nermost lay
nd the diver
ns elusive. 
sulting in t hProtoco
ssive, neuro
nited States 
suffering se
worldwide. 
ifestation o  
usative gen
monly inher i
al visual fiel d
ically. Unle
anced disea
field. In so m
nges in the r
ve pallor an
h are gradu a
bsequently 
esults in cha n
ell loss. Eve
er of the ret
se propertie
It is likely t
he activation l RST-001-CP
degenerativ e
(U.S.) is ap p
vere vision l
RP is most f r
fmany synd r
es and perha p
ited as an au t
d defects. A s
ss complica t
se. A patient 
me instance s
etina, classi c
d retinal va s
ally lost as t h
degenerate, t
nges in the i
n in the adv a
ina, persist a
s of the prot e
hat the mole c
of cell deat h-0001 Amend m
e disease of t
proximately 
loss from th i
requently 
romes. 
ps only 50 %
tosomal 
s the disease
ted by [CONTACT_606207] i
with advan c
s, all vision i
cally appear i
scular 
he disease 
together wit h
inner retina,
anced stage s
and maintain
eins they en c
cular pathol o
h pathways.ment 2
the 
is 
% of 
 
id 
ced 
is 
ing 
h the 
s, 
n their 
code, 
ogy 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-[ADDRESS_803031] little or no replicative function and cell 
loss results therefore in progressive deficit. 
3.1.5 Treatment 
Currently, there is no approved drug treatment for RP. Supplemental doses of Vitamin A may 
reduce the rate of degeneration in certain i ndividuals but the effects are insubstantial 
(Rayapudi et al., 2013 ). The Argus II retinal prosthesis (a n opto-electronic implant developed by 
[CONTACT_606208]., Sylmar , CA) has been approved by [CONTACT_1622], on a 
humanitarian basis, for those most severely affected by [CONTACT_143005]  (Dorn et al., 2013).  
3.2 Adeno-Associated Virus 
Adeno-associated virus (AA V ) is a parvovirus with a single-stranded DNA genome 
(Muzyczka N, Berns KI, 2001 ). It re quires a helper virus to complete its replication cycle in 
culture and in humans ( Blacklow NR, Hoggan MD, 1967) . AA V does not appear to integrate in 
humans ( Schnepp BC, et al 2005 ) and has not been associated with hum an disease ( Flotte TR, 
Carter BJ, 1995 ).  
3.3 Recombinant AA V Vectors 
Recombinant AA V (rAA V) vectors are composed of a transgene expression cassette between 
inverted terminal repeats (ITRs), which guide pa ckaging of vector DNA into AA V capsids. rAA V 
vectors are non-toxic, highly efficient at tran sducing a wide variety of  non-dividing cell types, 
and persist for long periods potentially leadi ng to long-term  expression of the transgene ( Carter 
PJ, Samulski RJ 2000 ).  
3.[ADDRESS_803032] been 
completed or are ongoing worldwide, some of which are in the area of ophthalmology, including indications like neovascular age-related macular degeneratio n, Leber Congenital Amaurosis 
(LCA), and choroideremia. 
3.[ADDRESS_803033]-001 (AGN-151597) is a gene therapy product   
 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-[ADDRESS_803034] ( ) to the highest  dose ( ). The objective of these 
studies was to test the behavioral  efficacy of a single-[ADDRESS_803035]-001 (dosing solutions ): (Low); (Mid);  (High)) on visual 
function in C3H/HeJ-Pde6brd1 mice ( ; hereafter “C3H”). These mice are 
homozygous for the retinal degeneration 1 mutation (Pde6brd1), which causes blindness by 
[CONTACT_606209]. The sighted control mice we re C3Sn.BLiA-Pde6b+/DnJ ( ; 
hereafter “C3Sn”). Behavioral assessments we re done prior to AA V2-ChR2 (RST-001) (when 
mice are ~ 8 weeks old; hereafte r “Baseline”), again starting at P120 (hereafter “Test 1”), and 
finally at [ADDRESS_803036] injection (hereafter “Test 2”). Viral in jections were done around [ADDRESS_803037]-001 at all dos es ( ) 
evaluated as compared with vehicle injected mi ce, based upon optokinetic responses. The highest 
dose ( ) also showed efficacy for visual placement responses. These effects were 
investigated in the high dose at [ADDRESS_803038] item-related microscopic findings were 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
16 noted in the tissues examined (brain, epi[INVESTIGATOR_4046], eye, heart, kidney, liver, lung, mandibular and 
mesenteric lymph nodes, optic nerve, paro tid salivary gland, spleen and testis). 
3.6.[ADDRESS_803039]-001 when given by a single intrav itreal injection and to evaluate the potential 
reversibility of any findings within 99 days of treatment.  
The following parameters and end points were evaluated: clinical signs, body weights, food 
consumption, ophthalmology, clinical pathology pa rameters  
 
, gross necropsy findings, organ weight s, and histopathologic examinations, and 
biodistribution.   

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
17 [IP_ADDRESS]  Mice Study 
The purpose of this study was to evaluate the toxici ty of the test article, RST-001, when given as 
a single 1 µL intravitreal injection in the right eye to C3H/HeJ-Pde6brd1 mice.   
Mice historically have been used in safety evaluation studies and this particular strain is a disease 
model for advanced RP, the indication of RST-001.  
There were 64 mice per dose group and 4 dose gr oups. Actual doses verified were: vehicle 
(control); (Low),  (Mid), a nd (High) vg/eye of RST-001.  After 
dosing, animals were observed post dose for at leas t 29 (interim sacrifice) or 89 days (terminal 
sacrifice). There were 16 animals/se x/group at each terminal sacrifice. 
There are no signs of test article related eff ects on body weights, food consumption, and clinical 
observations or during ophthalmic examinations through Week [ADDRESS_803040] above the minimu m level of detection

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
18 within the hindbrain and spleen. Dose-dependent  minimal to moderate ChR2 immunolabeling 
occurred in the right treated eye of animals given ; minimal ChR2 
immunolabeling was also present in the right  optic nerve of some animals with ChR2 
immunolabeling in the right eye. 
In conclusion, administration of RST-[ADDRESS_803041] been calcul ated by [CONTACT_606210]-clinical 
animal studies.  Vitreous humor volume was the scal ing factor across species. In general, scaling 
of the vitreous volume from mice and dogs to humans is 1:100 and 1:2, respectively.  Two 
nonclinical toxicology studies were conducted in the dog and mouse. The safe intravitreal doses 
in the dog ranged from . For the mouse, the sa fe intravitreal doses 
ranged from .  Two nonclinical pharmacology studies demonstrated 
efficacy and safety in the mouse at a dose range of  in a dose range 
comparable to the toxicology study. Based on thes e studies, the expected  safe dose range in 
humans is between  and . The dose range in this study ( to 
 of RST-001) is based on the more conservative exposure in the dog, inclusion of 
potentially efficacious doses, the ability of the manufacturer to concentrate investigational 
product, and a safe injection volum e of  per eye in humans.  
3.[ADDRESS_803042]-001 Study Rationale: Opt ogenetic Therapy for Advanced 
Retinitis Pi[INVESTIGATOR_606197]-[ADDRESS_803043] retinal cells, the retinal ganglion cells (RGCs) survive in significant numbers late into 
the disease and axons from these cells rema in connected directly to the brain.  
Direct electrical stimulation of  the RGCs using surgically-imp lanted electronic devices have 
provided a proof of concept that visi on can be mediated through these cells. 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-[ADDRESS_803044]-001 are shown in detail above. 
The study is composed of two phases. An initial  dose-escalation study (Phase 1) is proposed 
whereby [CONTACT_606211]-001 will be studie d in three separate groups of adult patients 
with advanced disease. Phase 1 is aimed at determining a single dose of the experimental 
treatment which is safe and well tolerated, to furt her evaluate in a fourth group of patients. If the 
Data Safety Monitoring Committ ee (DSMC) considers the safety  and tolerability of RST-[ADDRESS_803045] protocol as described in the Study Procedures Manual. 
3.9 Objectives of the Study 
3.9.1 Primary Objective: 
To evaluate the safety of a single intravitreal injection of RST-001. 
3.9.2 Secondary Objectives : 
1. To establish the maximum tolerated dose of RST-001. 
2. To evaluate the preliminary efficacy of RST-001 in patients with advanced RP. 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-[ADDRESS_803046] (IRB), and according to Good Clini cal Practice (GCP) standards.  No deviation 
from the protocol will be implemented without the prior review and approval of the IRB except 
where it may be necessary to eliminate an immediate hazard to a research patient.  In such case, 
the deviation will be reported to  the IRB as soon as possible. 
3.[ADDRESS_803047]-001 treatment and study procedures. 
[IP_ADDRESS]  Intravitreal Injection 
These risks are well recognized and include transient conjunctiv al hyperemia and hemorrhage at 
the injection site. Serious complications such as retinal tears/holes, retinal  detachment, vitreous 
hemorrhage and endophthalmitis are uncommon or rare but may result in reduced vision and may require surgical intervention. 
[IP_ADDRESS]  RST-[ADDRESS_803048]- 001 are not known. Potential risks include an 
immune response, which may result in ocular inflammation and the associated consequences. 
[IP_ADDRESS]  Study Procedures 
The risk from the tests performed in this study ca rry minimal risks and mostly relate to the need 
for pupi[INVESTIGATOR_179995], which typi[INVESTIGATOR_606198]. On occasion, a corneal abrasion can result from the use of the 
3.[ADDRESS_803049] has been manufactured in comp liance with current Good 
Manufacturing Practice (cGMP). Exte nsive testing has been performed to ensure infective agents 
and pathogens are not present. 
Intravitreal injection of RST-001 will be pe rformed in the operating room under aseptic 
conditions by [CONTACT_606212].  

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-[ADDRESS_803050]-001 will be m onitored (refer to Section 6.2.1).  
The conduct of this study will be overseen by [CONTACT_6802].  
3.[ADDRESS_803051] injection will be  managed in accordance with the investigator’s 
standard of care. 
It is not possible for RST-[ADDRESS_803052]-001 
administered as a single intravitreal in jection in patients with advanced RP.  
[IP_ADDRESS]  Enrollment Phase 1 
Three groups of patients (A, B, C, each compri sing of approximately but no less than three 
patients) will be enrolled in this study.  
Approximately [ADDRESS_803053]-001 (LOW). The safety 
and tolerability of RST-[ADDRESS_803054] patient for a mi nimum of one month (to 
include Month 1 Visit). If the DSMC considers th e safety and tolerability of the first patient 
satisfactory and the enrollment stopp ing rules have not been met, then the remaining patients in 
Group A can be enrolled and receive treatment.   

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-[ADDRESS_803055] not been met after a minimum assessment of one month (to include Month 1 
Visit) from the last treatment group, then appr oximately [ADDRESS_803056]-001 (MID) fo llowing the same guidelines and treatment 
schedule.  
Similarly, if the DSMC considers the safety and tolerability of Group B satisfactory and the 
enrollment stoppi[INVESTIGATOR_606199] a minimum assessment of one month (to 
include Month 1 Visit) from the last treatment group, then ap proximately [ADDRESS_803057]-001 (HIGH) following the same guidelines 
and treatment schedule. 
After completion of the 2-year core study visits , each patient will be enrolled in a long-term 
follow-up for an additional [ADDRESS_803058]-001. 
[IP_ADDRESS]  Enrollment Phase 2a  
If the DSMC considers the safety and tolerabi lity satisfactory and the enrollment stoppi[INVESTIGATOR_606200] a minimum assessment of  one month (to include Month 1 Visit) from 
treatment of the final patient in Groups A, B, or C, then the sponsor may elect to start enrollment 
in the second cohort of patients.  In Phase 2a, up to approximately [ADDRESS_803059]-001 at the maximum tolerated dose. 
• If the DSMC considers the data from Phase 1, in their opi[INVESTIGATOR_1649], to be indicative of a 
treatment benefit for visual acuity/function, then approximately 6 patients will be 
enrolled in Phase 2a and follow the same eligibility criteria as Phase 1. 
• If the DSMC considers the data fr om Phase 1, in their opi[INVESTIGATOR_1649], to not be indicative of a 
treatment benefit, then approximately [ADDRESS_803060] V A in the study eye to range from no-worse-than count fingers to 20/200 vision. 
A schematic providing an overview of the treatment schedule is illustrate d in Figure 1 , and the 
dose-escalation cohorts are illustrated in Table 1  below.  

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
23 Figure 1 Overview of the Treatment Schedule 
 
 
Table 1 Dose Escalation 
Phase  Group  Number of patientsa Intravitreal Injection 
Vector concentration  Volume 
 
1 A 3 LOW   
B 3 MID   
C 3 HIGH   
2a  6-12b Choice of dosec from 
groups A, B, or C   
a Up to approximately 21 patients w ill be enrolled in this study. 
b Number of patients is dependent upon whether or not the DSMC determines that, in their opi[INVESTIGATOR_1649], a treatment 
benefit for visual acui ty/function has been observed in Phase 1. 
c The maximum tolerated dose. 
 
After completion of the 2-year core study visits , each patient will be enrolled in a long-term 
follow-up for an additional [ADDRESS_803061]-001. 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
24 3.15.2  Study Population 
The study population consists of pa tients with advanced RP  
 
 This patient group is co nsidered to be a suitab le population to assess 
safety and tolerability in this Phase 1 study.  
 
  
Up to approximately 21 patients wi ll be enrolled in this study.  
3.15.3  Eligibility Criteria 
[IP_ADDRESS]  Inclusion Criteria 
The following are requirements for entry in the study:  
General Inclusion Criteria:  
1. Male or female patients, ≥ [ADDRESS_803062] menopausal (defined as last menstrua l period greater than two years prior to 
Baseline). Acceptable methods of contracep tion include hormonal contraception (i.e., 
birth control pi[INVESTIGATOR_3353], injected hormones, dermal patch or vaginal ring), intrauterine device, 
barrier methods (diaphragm, condom) with sp ermicide, or surgical sterilization (tubal 
ligation) 
5. Males must use two forms of contracepti on (including one barrier method for three 
months following study treatment administration if their partner is of child-bearing 
potential), or must be surgically sterile 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
25 Ocular Inclusion Criteria: 
Phase 1 and Phase 2a 
1. Diagnosis of advanced RP defined as: 
[IP_ADDRESS]  Exclusion Criteria 
Patients will not be excluded if the molecular diagnosis underlying their RP is not known or if 
there is presence of macular edema due to advanced RP.  
However, any one of the following will exclude patients from being enrolled into the study: 
General Exclusion Criteria:  
1. Participation in any investiga tional drug or device study within six months prior to Day 0; 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
26 4. Females who are pregnant, nursing, planning a pregnancy during the study or who are of 
childbearing potential not using a reliabl e method of contraception during their 
participation in the study  
5. History or current evidence of hypersensitivi ty to any component of the study treatment, 
medications, or diagnostic agents used in the study 
8. Any other condition that would not allow the potential patient to complete follow-up 
examinations during the course of the study and, in the opi[INVESTIGATOR_8598] e investigator, makes 
the prospective patient unsuitable for the study  
3.15.4  Early Discontinuation of Patients 
Patients may voluntarily withdraw from the study at any time or for the following reasons:  
a) Due to an adverse event (AE) 
b) If deemed necessary by [CONTACT_606213], the decision to withdraw a pati ent from study treatment or the study should be 
discussed with the sponsor. Notification of early patient discontinuation from the study and the 
reason for discontinuation will be clearly docum ented on the appropriate Case Report Form 
(CRF). 
In the case of a withdrawing patient, every reasonable attempt will be made to complete a final 
early termination visit (as shown in the study visi t table). Patients who withdraw from the study 
prior to receiving the stu dy treatment may be replaced. 

 
 
Approval Date :  
 19-Oct-2017Allergan  Protocol RST-001-CP-[ADDRESS_803063]-in-human study 
be  of this dose, . The MID dose will be  of the HIGH dose,  
 
Dose escalation will proceed accordin g to Table 1 , only after review by [CONTACT_6802] (see Figure 1 , 
above). Three doses have been chosen with the safety as the priority but will provide a good 
opportunity to observe biological effect. 
The rationale for the dosing schedule is once ag ain based primarily on patient safety. Thus, at 
each dose a single patient will receive treatment followed by [CONTACT_606214]. The safety and 
tolerability and optimal single dose of RST-[ADDRESS_803064]-001 is provided  
Please 
refer to the Study Procedures Manu al for additional information. 
4.8 Study Treatment Preparation and Administration 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
4.[ADDRESS_803065]-00
to continue 
e protocol (i
ve therapy).
eal In jectio
ble based on 
obtaining in
examinatiol RST-001-CP
documents i n
e handled in 
ministered to
e informed c
procedure d e
ontrolled ar e
nvestigator o
y, reconcilia t
ents, the inv e
untability re c
rgan or Alle r
ented by [CONTACT_606215], t
1. 
taking presc r
.e., antiplat e
on 
inclusion a n
formed cons e
n and labora t-[ADDRESS_803066] 
hout 
ee at 
r. 
onal 
to 

 
 
Approval Date :  
 19-Oct-2017Allergan  Protocol RST-001-CP-[ADDRESS_803067]-001 administration (Day 0) patients will 
be assessed on the first po st injection day (Day 1). 
The visit schedule includes: 
• Core study visits: Twelve visits are pla nned over 24 months, including Screening and 
Baseline visits, Day 0, Day 1, Day 7, and Months 1, 3, 6, 9, 12, 18, and 24. 
• Long-term follow-up: After completion of the Month 24 visit, each patient will 
participate in a long-term follow-up study for a total of an additional 13 years. These 
visits include yearly office visits for 5 year s (Months 36, 48, 60, 72, and 84) and yearly 
teleconference interviews for 8 years (Months 96, 108, 120, 132, 144, 156, 168, and 180). 
Core study visits are described in Table 2  and long-term  follow-up visits are described in Table 3 . 

 
 
Approval Date :  
 19-Oct-2017Allergan  Protocol RST-001-CP-0001 Amendment 2
 
31 Table 2 Study Visit Schedul e: Core Study Visits 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
32 Table 3 Study Visit Schedule: Long-term Follow-up Visits 
5.1 Schedule of Procedures by [CONTACT_606216] 2  and Table 3  for a schematic of the schedule of visits and procedures. 
5.1.1 Informed Consent and Patient Privacy 
The study will be discussed with the patient and patient’s impartial witn ess or legally acceptable 
representative. A patient wishing to participate must give informed consent and authorization 
prior to any study-related procedur es. The patient must also give  authorization (U.S. only) and 
other written documentation in accordance with  the relevant country and local privacy 
requirements (where applicable) prior to any stud y-related procedures or change in treatment. 
Each patient that provides informed consent and assent will be assigne d a patient number that 
will be used on patient documentation throughout the study. 
5.1.2 Screening Visit  
Prospective patients will be screened for eligibil ity up to 45 days prior to enrollment and the 
procedures will be performed as specified below. If convenient, the Screening and Baseline visits 
may be combined. 
It is the investigator’s responsib ility to review the results of a ll laboratory tests as they become 
available. This review will be documented by [CONTACT_093]’s dated signature [CONTACT_606231]. For each abnormal laborato ry test result in which the value of the test lies outside the 
normal range (see Appendix 2 f or reference values), the investigator needs to ascertain if this is 
an abnormal (ie, clinically significant) result fo r the individual subject. The investigator may 
repeat the laboratory test or request additional tests to verify the results of the original laboratory 
tests. If the laboratory value is determined by [CONTACT_606217], the subjec t will be excluded from the study.  

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
33 Records will be maintained of those individuals who are screened but do not meet the eligibility 
criteria for participation in the study. 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
34                                                  

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
35 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
36 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
37 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
38 5.1.14  Long-term Follow-up Visits 
Patients completing the Month 24 visit will participate in long-term follow-up visits. Patients 
will be asked to report any AEs that occur during this 13-year follow-up period. At Months 36, 
48, 60, 72, and 84, patients will undergo the following study assessments conducted at yearly 
clinic visits: 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-[ADDRESS_803068] been answered, written documentation of the informed consent decision will be obtained and the consent form will be countersigned by a witness to indicate informed consent 
was obtained.  
No study-related procedures will be performed un til after informed consent/assent is obtained.  
5.2.2 Medical History (Review)  
These will comprise: 
• Documentation of presenting co mplaints, and history thereof 
• Ocular medical and surgical history 
• General medical and surgical history 
• Current medication use (ocular and other) 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
40 5.2.3 Concomitant Medications and Procedures 
All medications and procedures will be recorded on the eCRF. If the permissibility of a specific 
medication/treatment is in question, the investigator is to contact [CONTACT_78562]. 
5.2.[ADDRESS_803069] 
Women of childbearing potential will undergo blood serum beta-hCG testing, to be analyzed at 
the site’s preferred certified laboratory. 
5.2.7 Blood Sample 
A venous sample will be collected from a peripher al vein and laboratory tests will be conducted 
at the preferred certified laboratory. 
Blood sample testing will include  
 
 
 
  
Instructions for shippi[INVESTIGATOR_606201]. 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
41 5.2.15  Complete Ophthalmic Examination 
A complete ophthalmic examination will be pe rformed in both eyes at the Screening and 
Baseline visits and at each visit after study tr eatment administration.  The examination will 
include  
 
 
 
 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
42 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
5.[ADDRESS_803070]-001-CP
n the Study P
t will be pre p
cording to t h
Pressure 
nagement o f
wering med i
e the intrao c
ular safety a n-0001 Amend m
Procedures 
pared using t
he investigat o
f a raised 
ications, ora l
cular pressu r
nd measures ment 2
the 
or’s 
l 
re. 
of 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
44 [IP_ADDRESS]  Ocular Inflammation 
Owing to the potential for intraocular inflammati on (as noted in the preclinical dog study) or 
immunogenicity, signs of ocular inflammation will be carefully monitored throughout the study 
and reported to the DSMC.  Active inflammation of the anterior chamber, vitreous and 
retina/choroid will be documented in the case report forms according to recognized international 
criteria shown in Table 4 , below.  Additional investigations,  
 may be performed at the discretion of  the investigator according to clinical findings 
and accepted standards of care. 
Table 4 Biomicroscopic Grading of Anterior Chamber Cells and Flare  
This is compliant with the standardizati on of uveitis nomenclature [SUN] working group 
(Jabs et al., 2005). 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
45 6.1.2 Systemic Safety Measurements 
1. Patient-reported and investigator-reported adverse events (AEs) 
2. Physical examination findi ngs including vital signs 
3. Findings of blood and serum laboratory testing 
4. Findings of immunological testing 
6. Other clinical and laboratory testing performed by [CONTACT_3170](s) based upon clinical 
observation, such as: 
• Vital signs 
• Clinical safety laboratory parameters 
• Immune response to RST-001 administration as  measured by [CONTACT_606218] 6.2.1 below . 
6.2 Clinical Management of  Safety Parameters  
The need for additional clinical evaluations, asse ssments and visits shall be determined by [CONTACT_1275](s) in accordance with accepted c linical practice and standards of care, where 
applicable. All activity will be recorded in the patient’s source documentation.  
Adverse events definitions and reporting requirements can be found in the Section 8.1 below. 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-[ADDRESS_803071]-001 will be monitored by [CONTACT_606219]: 
6.2.2 Complications of the Intravitreal Injection 
The complications of intravitr eal injection commonly include m ild conjunctival hyperemia and 
subconjunctival hemorrhage. Other uncommon co mplications include endophthalmitis, retinal 
tears/breaks/detachment, choroidal, vitreous and retinal hemorrhage.  
In all instances, management of these complications will be determined by [CONTACT_606220]/her practice and st andard-of-care, where applicable. 
6.2.[ADDRESS_803072]. 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
6.2.[ADDRESS_803073] at M
ntial effects 
Dat
Co
pendent Dat
study. The 
an(s) with e
Role 
mary role of 
y. The DSM
g any issues 
chedule for 
Resnanc y and
gnant at the 
aring potenti a
tudy.  In the 
l continue t o
ours of beco m
course of th e
onth [ADDRESS_803074]-
and/or Basel
red to maint
female bec
d in the stu
that a femal
male patient
tion visit. 
RST-001 ar e
Committ
mmittee (D
will compri
fresearch. 
he protectio
al progress a n
mposition an
etailed in th eProtoco
001 In Ute
ine visit wil
ain contrace
omes pregn
dy. The inve s
e patient or f
s of childbe a
e not known
ee (DSM
SMC) will b
se ophthalm o
n and safety 
nd conduct 
d responsibi
e DSMC Cl RST-001-CP
ero 
l be exclude d
ption durin g
ant during t h
stigator sho u
female part n
aring potenti a
. 
C) 
e formed to m
ologists, ph y
 of patients p
of the study 
lities, toget h
harter. -[ADDRESS_803075] i n
her with the ment 2
tudy.  
the 
e 
re a 
data 
g in 
n 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
7.4 
Enrollm
includin
the follo w
 8
Adverse 
events o
8.1 
8.1.1 
An adve
patient a
relations
unintend
associat
medicin
be asses
Note:  A
whether Enr
ent will be s
g causality t
wing events
Adv
events occu
ccur, the firs
Defi
Adv
rse event is 
dministered 
hip with thi
ed sign (inc
ed with the 
al (investiga
sed regardle
dverse even
or not the pollment St o
uspended p e
o determine 
:  
erse Even t
rring during
t concern w i
nitions 
erse Even t
any untowa r
a pharmace u
s treatment.  
luding an a b
use of a med i
tional) prod u
ss of the ad m
ts must be c o
atient has beoppin g Ru
ending a co m
the appropr i
ts 
 the study w
ill be the sa f
t 
rd medical o c
utical produ c
An adverse 
normal lab o
icinal (inves
uct.  In addi t
ministration o
ollected onc e
en administ e
[ADDRESS_803076] and that 
event can t
oratory findi
tigational) p
tion, during 
of a pharma
e informed 
ered study tProtoco
y review by t
continuing d
ded on an a d
udy partici
n a subject o r
does not nec e
herefore be 
ng), sympto
product, wh
the screenin
ceutical pro d
consent has 
reatment. l RST-001-CP
the sponso r o
osing in the 
dverse event 
pants.  
r clinical in v
essarily hav e
any unfavor a
m, or diseas e
ether or not r
g period, ad v
duct.   
been obtain e-0001 Amend m
of all patien t
occurrence o
CRF.  If ad v
vestigation 
e a causal 
able and 
e temporall y
related to th e
verse event s
ed, regardle sment 2
ts 
of 
verse 
y 
e 
s will 
ss of 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-0001 Amendment 2
 
49 Progression of treatment indicati on including new or worsening of anticipated clinical signs or 
symptoms, which are collected as clinical ef ficacy variables and assessed as unequivocally 
associated with the disease progression and/or lack of efficacy, should NOT be reported as 
adverse events unless the disease progression is greater th an anticipated in the natural course of 
the disease. 
Adverse events will be assessed, documented, and recorded in the CRF throughout the study (ie, 
after informed consent has been obtained).  At eac h visit, the investigator will begin by [CONTACT_606221] a genera l, non-directed question such as “How have 
you been feeling since the last visit?”  Directed questioning and examination will then be done as 
appropriate.  All reported adverse events will be documented on the appropriate CRF.   
8.1.2 Serious Adverse Event 
A serious adverse event is any adverse event oc curring at any dose that results in any of the 
following outcomes:  death, congenital anomal y or birth defect, significant disability, 
hospi[INVESTIGATOR_059], or life threatening.  Important medical events that ma y not result in death, be life-
threatening, or require hospi[INVESTIGATOR_316544] a serious adverse event when, based 
upon appropriate medical judgment, they may jeopa rdize the patient or patient and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition.  
Allergan considers all cancer adverse events as serious adverse events.  In addition, Allergan 
considers any abortion (spontaneous or nonspontaneous) as a serious adverse event. 
Preplanned surgeries or procedures for pre- existing, known medical conditions for which a 
patient requires hospi[INVESTIGATOR_249590] a serious adverse event. 
Any preplanned surgery or proced ure should be clearly documented in the site source documents 
by [CONTACT_606222]’s entry into the study.  If it has 
not been documented at the time of the patien t’s entry into the study, then it should be 
documented as a serious adverse ev ent and reported to Allergan. 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-[ADDRESS_803077] be  completed using the following definitions as 
guidelines: 
Mild Awareness of sign or symptom, but easily tolerated. 
Moderate Discomfort enough to cause interference with usual activity. Severe Incapacitating with inability to work or do usual activity. 
8.1.4 Relationship to Study Drug or Study Procedure 
A determination will be made of the relationship (if any) between an adverse event and the study 
drug or study procedure, as applicable.  A causa l relationship is present if a determination is 
made that there is a reasonable possibility that the adverse event may have been caused by [CONTACT_606223]. 
A study procedure occurring duri ng the screening/baseline peri od can include a study required 
diagnostic procedure. For treatment-related adverse events, the investigator will note on the CRF whether the event is 
related to the study drug, and/ or the injection procedure. 
8.[ADDRESS_803078] be recorded on the appropriate CRF. 
All adverse events that are drug- related and unexpected (not listed as treatment-related in the 
current Investigator's Brochure) must be report ed to the governing IRB as required by [CONTACT_1201], 
local regulations, and the governi ng health authorities.  Any ad verse event that is marked 
“ongoing” at the exit visit must be followed-up as appropriate. 
8.3 Procedures for Reporting a Serious Adverse Event 
Any serious adverse event occurring during the study period (beginning with informed consent) 
and for at least [ADDRESS_803079] be reported to Allergan (or 
Agent of Allergan) as listed on the Allergan St udy Contacts Sheet and r ecorded on the serious 
adverse event form.  All patients with a seriou s adverse event must be followed up and the 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
outcome
requeste
In the ev
1. 
(
n
2. 
p
3.
 P
sg
S
c
a
e
4. 
P
l
 [ADDRESS_803080] deta
umbers and 
Obtain and 
medical judg
atient. 
rovide Alle
erious adve
iven (eg, m
ummarize r
linical cour
lternative e
vent was or 
romptly inf
ocal regulati
Effic
y of paramet
identify a siThe investi g
n (eg, autop
ous adverse 
gan immedia t
ils can be fo u
relevant All
maintain in h i
ments from c
rgan with a c
rse event for m
edications a d
elevant clini
se and relev a
xplanation(s )
was not rel a
orm the gov e
ons, and the 
cacy Asses
ers that enc o
gnal of effic agator must s u
sy reports a n
event, the i n
tely by [CONTACT_6791] o
und on pag e
ergan perso n
is/her files a
colleagues w
complete, w r
m describin g
dministered, 
cal informa t
ant clinical l a
) for the cau s
ated to the u s
erning IRB o
governing h
sments 
ompass visu a
acy, as follo w
[ADDRESS_803081] s
ll pertinent 
who assiste  
ritten descri p
g the event c
procedures 
tion about t
aboratory te
sality which 
se of the inv
of the serio u
health autho
al function 
ws: Protoco
an and the I
e summaries
must: 
ng the serio u
rious advers
s are also o n
medical rec
d in the treat m
ption of the 
chronologic
performed) 
he event:  si
sts, etc.  Inc
 includes a s
estigational 
us adverse e v
rities. 
will be eval ul RST-001-CP
RB with an y
).  
us adverse e v
e event for m
n the front p a
ords, inform a
ment and fo l
adverse eve n
ally, includi n
for the adv e
gns, sympto m
lude any ad d
statement as 
drug. 
vent as requ i
uated in the s-0001 Amend m
y additional 
vent form 
m); phone 
age of proto c
ation, and 
llow-up of t h
nt(s) on the 
ng any treat m
erse event(s)
ms, diagnos i
ditional or 
to whether t
ired by [CONTACT_941] I R
study eye in ment 2
col. 
he 
ment 
.  
is, 
the 
RB, 

 
 
Approval Date :  
 19-Oct-2017Allergan
 
 10
10.1 
A repres e
the exte
purpose, 
represen
review, 
investig
and ques
10.2 
The studpatient h
 11
11.1 
The pri
11.2 
11.2.1  Clin
Mon
entative of t
nt and natur
design, co
tatives of Al
audit and co p
ator(s) and a
tions. 
Stu
y can be ter
as complete
Dat
Prim
mary endpoi
SecoMeaical Moni t
itorin g  
he sponsor w
e of monitor i
mplexity, bli n
lergan or re g
py study-rel a
ppropri ate st
dy and Sit e
minated at a n
d study visi t
a Anal ysis 
mary (Safe t
nt is safety a
ndary End
sures of Ctoring Stru
will monitor 
ing will be b
nding, size, a
gulatory aut h
ated docum e
taff at mutu a
e Closure
ny time. Th e
ts and asses s
and Stati s
ty) Endp o
t [ADDRESS_803082] o
ves will mee t
discuss stu d
ed complete 
ns -0001 Amend m
eterminatio n
objective, 
ed 
on-site visits
t with the 
dy-related d a
after the fi nment 2
n of 
 to 
ata 
nal 

 
 
Approval Date :  
 19-Oct-2017Allergan Protocol RST-001-CP-[ADDRESS_803083] deviation, minimum, median and 
maximum. 
11.3.1  Power and Sample Size Considerations  
The sample size for this study was chosen empi[INVESTIGATOR_606202]; no formal sample size computations to 
meet power requirements were made. The sample size of approximately 3 patients for each dose group in Phase 1 are typi[INVESTIGATOR_606203], an additional up to approximately12 
patients will be enrolled in Phase 2a fo r further safety and efficacy evaluation. 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
13.1.2  
• S
i
 14
The spofor any r
closed 
w
closure 
The inve
and suffi
Reasons 
not lim
it
• Fl
• I
• Sou
ource docu
ntegrity of t
Stu
nsor designe
eason.  Stu
hen all requ
visit has bee
stigator ma
cient notice 
for the earl
ed to: 
ailure of th
ocal health 
nadequate r
Discontinuatrce Docu m
ments provi d
he data colle
dy Termin a
e reserves t h
dy sites will b
ired docum e
n performed .
y initiate stu d
is given in a
y closure of a
e investigato r
authorities, t h
ecruitment o f
ion of furth ements 
de evidence f
cted. Sourc e
ation 
he right to cl o
be closed u p
ents and stu d
. 
dy-site clos u
advance of t h
a study site b
r to comply 
he sponsor’ s
f patients by
[CONTACT_606224] t
[ADDRESS_803084]-001-CP
patient and s
the investig a
minate the s t
study site i s
ollected and 
d there is re a
. 
igator may i n
equirements 
idelines -0001 Amend m
substantiate t
ator’s site. 
tudy at any t
s considered 
a study-site 
asonable ca u
nclude but a
of the IRB oment 2
the 
time 
use 
are 
or 

 
 
Approval Date :  
 19-Oct-2017Allergan
 
 15
15.1 
This sec
(http://cl
The goal
or incre a
possible effective
harm for 
purpose 
the scie
n
The ethinotoriou
withheld of the di
studies. 
Some
 of 
include: 
• 
• 
• 
• 
• 
Using th
guiding 
• S
• S
• F
• FReg
Ethi
tion has bee
inicalcenter.
 of clinical ses underst
to secure th
, for examp
the good o  
of ethical g
ce. 
cal guidelin
s of which i
from 400 
sease. Vario
the influent
Nuremberg 
Declaration 
Belmont Rep
CIOMS ([ADDRESS_803085] 
ocial and cl
cientific valair patient
 s
avorable risulator y an
cal Cond u
n extracted f
nih.gov/rec r
research is t o
anding of hu m
at knowledg
le, is to test i
fothers, clin
uidelines is b
es in place t o
n America w
African Ame r
us ethical g u
ial codes of 
Code (1947) 
of Helsinki (
ort (1979) 
2) 
n Rule ([ADDRESS_803086] of the S
from the NI H
ruit/ethics.h t
o develop g e
man biolog y
e. The path t
it on patient 
ical researc h
both to prote
oday were p r
was an exper i
rican men w i
uidelines we r
ethics and r e
2000) 
1) 
and others, s
search: 
tio 
57 Consider
Study 
H guidance o
tml): 
eneralizable 
y. People w
to finding o
volunteers. 
h has the pot
ct patient v
rimarily a re
iment in Tu s
ith syphilis 
re develope d
egulations t h
seven main pProtoco
ations 
on Ethics in 
knowledge 
ho participat e
ut if a new 
But by [CONTACT_606225] p
olunteers an
sponse to p
skegee, Ala
so that scie
d in the 20t  
hat guide et
principles hl RST-001-CP
Clinical Re s
that improv e
e in clinical 
drug or treat m
ing some pe o
ploit patient v
d to preserv e
ast abuses, t h
bama, in whi
ntists could s
h century in r
hical clinical
ave been de s-[ADDRESS_803087] 
ch treatmen t
tudy the co u
response to s
l research 
scribed as ment 2
alth 
ake it 
or 
of 
The 
ty of 
t was 
urse 
such 

 
 
Approval Date :  
 19-Oct-2017Allergan  Protocol RST-001-CP-0001 Amendment 2
 
58 • Independent review 
• Informed consent 
• Respect for potential and enrolled patients 
Social and clinical value 
Every research study is designed to answer a spec ific question. Answering certain questions will 
have significant value for society or for present or future patients  with a particular illness. An 
answer to the research question should be important or valuable enough to justify asking people 
to accept some risk or inconvenience for others. In other words, answers to the research question 
should contribute to scientific understanding of health or improve our ways of preventing, 
treating, or caring for people with  a given disease. Only if soci ety will gain useful knowledge — 
which requires sharing results, both negative a nd positive — can exposing human patients to the 
risk and burden of research be justified. 
Scientific validity 
A study should be designed in a way that will get an understandable answer to the valuable 
research question. This includes considering whether the question researchers are asking is 
answerable, whether the research methods are valid and feasible, and whether the study is 
designed with a clear scientific objective and using accepted principles, methods, and reliable 
practices. It is also important that statistical plan s be of sufficient power to definitively test the 
objective, for example, and for data analysis. Invalid  research is unethical because it is a waste of 
resources and exposes people to risk for no purpose. 
Fair patient selection  
Who does the study need to include, to answer th e question it is asking? The primary basis for 
recruiting and enrolling groups and individuals should be the scient ific goals of the study — not 
vulnerability, privilege, or other factors unrelated to the purposes  of the study. Consistent with 
the scientific purpose, people s hould be chosen in a way that minimizes risks and enhances 
benefits to individuals and society. Groups and individuals who accept the risks and burdens of 
research should be in a position to enjoy its benefits, and those who ma y benefit should share 
some of the risks and burdens. Specific groups or  individuals (for example, women or children) 
should not be excluded from the opportunity to pa rticipate in research without a good scientific 
reason or a particular su sceptibility to risk. 
Favorable risk-benefit ratio  
Uncertainty about the degree of risks and benefits  associated with a drug, device, or procedure 
being tested is inherent in clinical research — otherwise there would be little point to doing the 
research. And by [CONTACT_108], there is more uncerta inty about risks and benefits in early-phase 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
research 
trivial or 
(death, d
(for exa
this stud y
research to indivi
d
Indepen
To mini
even sta
review t
sufficien
been eth
evaluati
boards (
while it 
 16
16.1 
The inve
Impleme
Protocol 
required.
 17
Allergan 
composi
personn
involves 
final rep o
 18
A final rthan in late
serious, mi
isability, in
mple, discri
y, reasonabl
patients, to 
duals and so
dent revie
mize potenti
rts, an indep
he proposal 
tly free of b
ically desig
on of resear c
IRBs), and 
is ongoing. 
Man
Prot
stigator wil
ntation of c
Amendmen
 
Pub
as the spon
tion will ref
el. Authorsh
multiple ce
ort of the m u
Spo
eport will br research. D
ght cause tr a
fection), psy c
mination or s
e efforts ha v
maximize t h
ciety are pr o
w 
al conflicts o
endent revie
and ask imp o
ias? Is the s t
ned and is th e
h projects i s
Data Safety M
agement o
ocol Ame n
l conduct th e
hanges to th e
t(s) by [CONTACT_941] s p
lication P o
sor, has pro p
lect joint co o
ip will be es t
nters, no in d
ulticenter st u
nsor's Fin a
e prepared b yDepending o n
ansient disc o
chological ( d
stigma from 
ve been take n
he potential b
oportionate t
of interest a n
w panel wit h
ortant quest i
tudy doing a
e risk– benef
s done throu g
Monitoring C
of Protoc o
ndments 
e study in ac c
e protocol w
ponsor, inve
olicy 
prietary inte r
operation be t
tablished pr i
dividual pub l
udy except a
al Report
y the spons o
[ADDRESS_803088] in this s
tween multi p
ior to the wr
lications wil
s agreed wi
or. Protoco
lars of a stu
ng-term cha
anxiety), ec
g in a certai n
ze the risks a
d to determi
igh, the risk
e a study is e
interest in t
ing: Are tho s
rotect resea
rable? In th
agencies, lo c
. These gro
ments and 
ith this Clin i
made follow i
titutional R
tudy. Autho r
ple investig a
iting of the 
l be allowe
th Allergan.l RST-001-CP
dy, research 
nges. Risks c
onomic (job 
n study). Pri o
and inconve n
ne that the p o
s.  
ethically ac c
he particular 
se conducti n
rch volunte e
e United St a
cal instituti o
ups also mo n
Deviatio n
ical Study P r
ing review a
eview Boar d
rship and m a
ators and sit e
manuscript. A
d prior to co m-0001 Amend m
risks might 
can be physi
loss), or so c
or to initiati n
nience to 
otential ben e
ceptable bef o
study shou l
ng the study 
ers? Has the 
ates, indepe n
onal review 
nitor a study 
ns  
rotocol. 
and approva l
d and the FD A
anuscript 
es and Aller g
As this stud y
mpletion of tment 2
be 
cal 
cial 
ng 
efits 
ore it 
ld 
study 
ndent 
l of 
A, as 
gan 
y 
the 

 
 
Approval Date :  
 19-Oct-2017Allergan
 
 19
Blacklo w
Proc Na t
Carter P
2000;6:1
Daiger S
pi[INVESTIGATOR_606204] T
1995;2:[ADDRESS_803089] Int e
Klein M ,
degenerOphthal
Muzycz
PM, eds.
Nussenb
activity i
Rayapu
pi[INVESTIGATOR_606205]. 2Refe
w NR, Hogg
l Acad Sci 
J, Samulski 
7-27. 
P, Bowne S
osa. Arch O
, Ahuja AK, 
by [CONTACT_606226]. 2013;1
R, Carter BJ
57-362. 
, Nussenbla
, G. Standar
ernational 
, Birch DG. 
ative disease
mol. 2009;1
ka N, Berns 
 Fields Viro
latt RB, Pal
n intermedi
di S, Schwar
osa. 2013. C
BC, Jensen 
ed virus gen
MM, Daige
ce of mutati
001;17:42-5rences 
an MD and R
[LOCATION_003]. 1967; 5
RJ. Adeno- a
J, and Sulli v
phthalmol. 2
Caspi A, d a
ects with th e
31:183-189. 
. Adeno-ass o
tt RB, Rose n
dization of u
Workshop. A m
Psychophys
s (RDDs) w i
19:217–224. 
KI. Parvovi r
logy. Philad e
estine AG, C
ate and post e
tz SG, Wan g
ochrane Da t
RL, Chen C
omes isolate d
r SP, Bown e
ons causing 
1. Rowe WP. I s
58:1410-141 5
associated vi r
an LS. Pers p
007;125:15
a Cruz L, Da g
e epi[CONTACT_190773] 6
ociated viru s
nbaum JT, a n
uveitis nom e
m J Ophthal m
ical assess m
ith the Diag n
ridae: the vi r
elphia: Lipp
Chan C, Rob e
erior uveitis .
g X, and Ch a
tabase Syst R
CL, Johnson 
d from hum a
 SJ, Rodriq u
retinitis pig m
[ADDRESS_803090] i
enclature fo  
mol. 2005;1
ment of low 
nosys full-fi
ruses and th
incott Willi a
erge F. Stan d
. Ophthalm
avis P.  Vita m
Rev 12, CD
PR and Cla r
an tissues. J 
uez JA, Nor t
mentosa anProtoco
adeno virus-
as gene deli
enes and m
ahel JA, gus ,
e (argus II) r
gene thera
ization of U
r reporting c l
40:509-516.
visual functi
eld stimulu
eir replicati o
ams & Wilk
dardization 
ology. 1985; [ADDRESS_803091] h
py. Gene Th e
veitis Nome n
linical data. 
on in patien t
s threshold ( D
on. In: Knip e
ins, 2001:23
of vitreal in f
92:467–471 .
sh oils for r e
racterization 
;79:[ZIP_CODE]-[ADDRESS_803092]). Do
e DM, How l
27-2359. 
flammatory 
. 
etinitis 
of adeno 
4803. 
R, Sullivan L
athies. Hum ment 2
man. 
Med. 
of 
A
he 
al 
c 
ley 
LS. 

 
 
Approval Date :  
 19-Oct-2017Allergan 
 
 [ADDRESS_803093]-001 
[LOCATION_003] 
VFQ 
 App
Appendices 
endix 1: A
Adverse Ev e
Aspartate a m
Best Correc t
Degrees Cel
Code of Fe d
Case Report 
Common T e
Dose Limiti n
Deoxyribon u
Data Safety 
Early Treat m
Food and D r
First-in-Hu m
Good Clinic
Good Labor a
Good Manu f
Investigatio n
Intraocular P
Immediatel y
Internationa l
Millimeters 
National Ey e
National Ins t
Quality of L
Retinal Gan g
Retinitis Pi g
RetroSense 
United Stat e
Visual Func tAbbreviati o
ent 
minotransferas e
ted Visual Ac u
sius 
deral Regulatio n
Form 
erminology Cr i
ng Toxicity 
ucleic Aci d 
Monitoring C o
ment for Diabe t
rug Administr a
man 
al Practice 
atory Practice
facturing Prac t
nal New Drug
Pressure 
y Reportable A
l Society for C
e Institute 
titutes of Heal t
ife 
glion Cells 
gmentosa 
Therapeutics d
es of America 
tioning Questi o
[ADDRESS_803094] (
onnaire Protoco
rse Events 
y Stud y 
physiology of 
AGN-151597)l RST-001-CP
Vision -0001 Amend mment 2
